We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $322.78 · 9 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
KRYS Technical Analysis & Stock Price Forecast - Intellectia AI
KRYS Technical Analysis & Stock Price Forecast Intellectia AI
Insider Sell: John Thomas Sells Shares of Krystal Biotech Inc (K - GuruFocus
Insider Sell: John Thomas Sells Shares of Krystal Biotech Inc (K GuruFocus
Krystal Biotech EVP, general counsel sells $193,903 in shares By Investing.com - Investing.com Nigeria
Krystal Biotech EVP, general counsel sells $193,903 in shares By Investing.com Investing.com Nigeria
Does UK Approval of At‑Home VYJUVEK Dosing Reshape the Bull Case for Krystal Biotech (KRYS)? - simplywall.st
Does UK Approval of At‑Home VYJUVEK Dosing Reshape the Bull Case for Krystal Biotech (KRYS)? simplywall.st
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock - Yahoo Finance
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock Yahoo Finance
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 03. | After market close (AMC) | $1.94 | — | — | $125.25M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $1.2 | — | — | $88.18M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $1.47 | — | — | $199.38M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $0.56 | — | — | $115.54M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 22. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 05. 18. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
Compare a firm's past rating changes and its actions on other stocks in the same sector.
As of FY2026Q1 · Source: SEC/DART + price data
Filings, earnings, and institutional changes summarized in one paragraph, with source links.
No holdings data to show.
See new positions, full exits, and weight changes.